Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $23 from $25 and keeps an Outperform rating on the shares. The firm notes the Avlayah launch is now underway with initial patients receiving treatment. There is no change to Wedbush’s below consensus revenue estimates as the initial quarters lay the groundwork.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy
- Denali Therapeutics price target raised to $34 from $32 at Baird
- Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
- Denali Therapeutics price target raised to $39 from $38 at BTIG
- Denali Therapeutics regains full rights to DNL593